[go: up one dir, main page]

MA26753A1 - Composes therapeutiques, procedes pour les preparer et medicaments les contenant - Google Patents

Composes therapeutiques, procedes pour les preparer et medicaments les contenant

Info

Publication number
MA26753A1
MA26753A1 MA26080A MA26080A MA26753A1 MA 26753 A1 MA26753 A1 MA 26753A1 MA 26080 A MA26080 A MA 26080A MA 26080 A MA26080 A MA 26080A MA 26753 A1 MA26753 A1 MA 26753A1
Authority
MA
Morocco
Prior art keywords
hydrogen
amino
processes
lower alkyl
compounds
Prior art date
Application number
MA26080A
Other languages
English (en)
Inventor
Alanine Alexander
Burner Serge
Buttelmann Bernd
Heitz Neidhart Marie-Paul
Jaeschke Georg
Pinard Emmanuel
Wyler Rene
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26753A1 publication Critical patent/MA26753A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSÉS THÉRAPEUTIQUES, PROCÉDÉS POUR LES PRÉPARER ET MÉDICAMENTS LES CONTENANT F. HOFFMANN-LA ROCHE AG La présente invention concerne des composés de formule générale dans laquelle R1 est un hydrogène, un halogène ou un groupe alkyle inférieur, alcoxy inférieur, hydroxy, amino, nitro, cyano, alkylamino inférieur ou dialkyl-amino inférieur ; R2 est un hydrogène ou un groupe alkyle inférieur, amino, pyrrolidin-3-ol, pyrrolidin-2-ylméthanol ou -NHCH2CHROH ; R3 est un hydrogène ou un halogène ; R est un hydrogène ou un groupe alkyle inférieur ou -CH2OH ; n vaut 1 ou 2 ; et leurs sels d'addition d'acides pharmaceutiquement acceptables. Les composés de la présente invention sont des agents bloquants sélectifs d'un sous-type de récepteur de NMDA (N-méthyl-D-aspartate) qui possèdent une fonction primordiale dans la modulation de l'activité et la plasticité neuronales dans des processus de médiation sous-jacents au développement du système nerveux central ainsi qu'à l'apprentissage et à la formation de la mémoire.
MA26080A 1999-10-08 2000-10-04 Composes therapeutiques, procedes pour les preparer et medicaments les contenant MA26753A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99120131 1999-10-08

Publications (1)

Publication Number Publication Date
MA26753A1 true MA26753A1 (fr) 2004-12-20

Family

ID=8239160

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26080A MA26753A1 (fr) 1999-10-08 2000-10-04 Composes therapeutiques, procedes pour les preparer et medicaments les contenant

Country Status (26)

Country Link
US (1) US6339093B1 (fr)
EP (1) EP1090917B1 (fr)
JP (1) JP3385318B2 (fr)
KR (1) KR100398562B1 (fr)
CN (1) CN1162424C (fr)
AR (1) AR032601A1 (fr)
AT (1) ATE313538T1 (fr)
AU (1) AU777881B2 (fr)
BR (1) BR0004709A (fr)
CA (1) CA2322309C (fr)
DE (1) DE60024947T2 (fr)
DK (1) DK1090917T3 (fr)
EG (1) EG23872A (fr)
ES (1) ES2254095T3 (fr)
HR (1) HRP20000652A2 (fr)
HU (1) HUP0003938A2 (fr)
ID (1) ID27526A (fr)
IL (1) IL138916A0 (fr)
MA (1) MA26753A1 (fr)
MX (1) MXPA00009771A (fr)
NO (1) NO20005031L (fr)
NZ (1) NZ507303A (fr)
PE (1) PE20010660A1 (fr)
PL (1) PL343057A1 (fr)
TR (1) TR200002893A2 (fr)
ZA (1) ZA200005447B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
EP1436258A4 (fr) * 2001-03-08 2005-03-23 Univ Emory Antagonistes du recepteur nmda dependant du ph
US6831087B2 (en) 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
MY146992A (en) * 2007-06-18 2012-10-15 Richter Gedeon Nyrt Sulfonyl-quinoline derivatives
JP2010532382A (ja) * 2007-06-29 2010-10-07 エモリー・ユニバーシテイ 神経保護のためのｎｍｄａ受容体拮抗薬
AU2008304231A1 (en) * 2007-09-27 2009-04-02 Albany Molecular Research, Inc. Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
LT3386591T (lt) 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
EP3452465B1 (fr) * 2016-05-04 2020-11-04 Genoscience Pharma Dérivés de 2,4-diamino-quinoléine substitués à utiliser dans le traitement de maladies prolifératives
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
JP7319369B2 (ja) 2018-08-03 2023-08-01 ノバルティス アーゲー ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8409745D0 (en) * 1984-04-14 1984-05-23 Beecham Group Plc Active compounds
US4560692A (en) * 1984-07-18 1985-12-24 Hoffmann-La Roche Inc. 4-Piperidino-2-phenylquinolines
GB8716972D0 (en) * 1987-07-17 1987-08-26 Pfizer Ltd Treatment of cardiac arrhythmias
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
GB9203798D0 (en) * 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5567718A (en) * 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US6339093B1 (en) * 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
BR0004709A (pt) 2001-06-12
DE60024947D1 (de) 2006-01-26
US6339093B1 (en) 2002-01-15
EG23872A (en) 2007-11-27
TR200002893A3 (tr) 2001-04-20
EP1090917B1 (fr) 2005-12-21
HU0003938D0 (en) 2000-12-28
EP1090917A1 (fr) 2001-04-11
ATE313538T1 (de) 2006-01-15
TR200002893A2 (tr) 2001-04-20
AU6410000A (en) 2001-04-12
DK1090917T3 (da) 2006-04-24
ZA200005447B (en) 2001-04-09
CA2322309A1 (fr) 2001-04-08
PL343057A1 (en) 2001-04-09
CA2322309C (fr) 2008-05-20
JP2001114777A (ja) 2001-04-24
DE60024947T2 (de) 2006-09-21
ES2254095T3 (es) 2006-06-16
KR20010050915A (ko) 2001-06-25
PE20010660A1 (es) 2001-06-26
KR100398562B1 (ko) 2003-09-19
JP3385318B2 (ja) 2003-03-10
HUP0003938A2 (hu) 2002-11-28
ID27526A (id) 2001-04-12
NO20005031D0 (no) 2000-10-06
AU777881B2 (en) 2004-11-04
NZ507303A (en) 2002-09-27
CN1162424C (zh) 2004-08-18
AR032601A1 (es) 2003-11-19
CN1304936A (zh) 2001-07-25
IL138916A0 (en) 2001-11-25
NO20005031L (no) 2001-04-09
MXPA00009771A (es) 2002-10-23
HRP20000652A2 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
MA26753A1 (fr) Composes therapeutiques, procedes pour les preparer et medicaments les contenant
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
TNSN05165A1 (fr) Derives de pyrrolopyrimidine
TNSN96161A1 (fr) Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant.
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
TNSN97055A1 (fr) Derives de 6-phenylpyridyl -2- amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27754A1 (fr) Pyrimidinones substituees
AU2002318302C1 (en) Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26696A1 (fr) Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
TNSN97087A1 (fr) 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00232A1 (fr) Derives de 2,4-diaminopyrimidine nouveaux, et compositions les contenant
TNSN98151A1 (fr) Derives de 2 - (4 - aryl - ou heteroaryl - piperazine - 1 - ylmethyl) -1 h - indole.
MA28742B1 (fr) Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique
US6821976B2 (en) S-6-hydroxy-buspirone